EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte Studie

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

Toni K Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Naomi B Haas, Howard Gurney und 22 weitere

New England Journal of Medicine · 18.04.2024 · 390 (15) · 1359-1371

DOI: 10.1056/nejmoa2312695 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 18.04.2024. Verfasst von Toni K Choueiri und 33 weiteren Autor:innen. Beteiligte Einrichtung: From Dana-Farber Cancer Institute and Harvard Medical School (T.K.C.) and Beth Israel Deaconess Medical Center (D.F.M.) - all in Boston; Poznan Unive…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 365-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsAntineoplastic Agents, ImmunologicalHumansAdjuvants, ImmunologicAntibodies, Monoclonal, HumanizedDouble-Blind MethodDisease-Free SurvivalCombined Modality TherapySurvival Analysis

Substanzen

Adjuvants, ImmunologicAntibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • From Dana-Farber Cancer Institute and Harvard Medical School (T.K.C.) and Beth Israel Deaconess Medical Center (D.F.M.) - all in Boston; Poznan University of Medical Sciences, Poznan (P.T.), and Provincial Hospital in T…

Förderung

  • Merck

Zitieren

APA

Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Chang, Y. H., Lee, J. L., Sarwar, N., Haas, N. B., Gurney, H., Sawrycki, P., Mahave, M., Gross-Goupil, M., Zhang, T., Burke, J. M., Doshi, G., Melichar, B., …, & KEYNOTE-564 Investigators (2024). Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. New England Journal of Medicine, 390(15), 1359-1371. https://doi.org/10.1056/nejmoa2312695

Vancouver

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, et al. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. New England Journal of Medicine. 2024;390(15):1359-1371. doi:10.1056/nejmoa2312695

BibTeX
@article{Choueiri2024,
  author = {Choueiri, Toni K and Tomczak, Piotr and Park, Se Hoon and Venugopal, Balaji and Ferguson, Tom and Symeonides, Stefan N and Hajek, Jaroslav and Chang, Yen-Hwa and Lee, Jae-Lyun and Sarwar, Naveed and Haas, Naomi B and Gurney, Howard and Sawrycki, Piotr and Mahave, Mauricio and Gross-Goupil, Marine and Zhang, Tian and Burke, John M and Doshi, Gurjyot and Melichar, Bohuslav and Kopyltsov, Evgeniy and Alva, Ajjai and Oudard, Stephane and Topart, Delphine and Hammers, Hans and Kitamura, Hiroshi and McDermott, David F and Silva, Adriano and Winquist, Eric and Cornell, Jerry and Elfiky, Aymen and Burgents, Joseph E and Perini, Rodolfo F and Powles, Thomas and KEYNOTE-564 Investigators, KEYNOTE-564 Investigators},
  title = {Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {15},
  pages = {1359--1371},
  doi = {10.1056/nejmoa2312695}
}
Kostenlos starten →